A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).

Name: A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
Published: 2008
License: Public Domain

Genzyme, a Sanofi Company · 2008

ClinicalTrials.gov · Datasets · License: Public Domain · 2008

Open Source ↗

lymphoma multiple-myeloma transplantation

lymphoma (non-hodgkin's lymphoma), hodgkin's disease or multiple myeloma, front line mobilization, transplantation, mobilisation stem cells, g-csf mobilisation regimen, lymphoma, multiple myeloma, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).

Related documents